Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pharmaxis raises A$50 million

Pharmaxis (ASX:PXS; PXSL) raised A$50 million (US$44.9 million) through the sale of 12.8 million

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE